China SXT Pharmaceuticals, Inc.
SXTC
$1.07
-$0.05-4.46%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -38.80% | -31.76% | -24.23% | 4.57% | 43.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -38.80% | -31.76% | -24.23% | 4.57% | 43.10% |
| Cost of Revenue | -38.94% | -15.82% | 14.41% | 12.12% | 10.20% |
| Gross Profit | -38.56% | -53.67% | -65.95% | -9.46% | 196.91% |
| SG&A Expenses | 215.31% | 81.22% | -11.75% | -22.14% | -32.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.27% | 59.66% | -7.22% | -15.81% | -23.98% |
| Operating Income | -290.20% | -116.64% | -1.31% | 23.91% | 44.84% |
| Income Before Tax | -241.74% | -110.29% | -9.74% | 20.89% | 43.51% |
| Income Tax Expenses | -- | -- | -- | -98.94% | 102.36% |
| Earnings from Continuing Operations | -241.56% | -103.26% | -3.47% | 22.25% | 42.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -241.56% | -103.26% | -3.47% | 22.25% | 42.69% |
| EBIT | -290.20% | -116.64% | -1.31% | 23.91% | 44.84% |
| EBITDA | -312.33% | -125.67% | -2.83% | 23.77% | 45.72% |
| EPS Basic | 54.69% | 74.71% | 83.42% | 77.03% | 73.08% |
| Normalized Basic EPS | 55.90% | 74.20% | 82.76% | 76.89% | 73.58% |
| EPS Diluted | 54.69% | 74.71% | 83.42% | 77.03% | 73.08% |
| Normalized Diluted EPS | 55.90% | 74.20% | 82.76% | 76.89% | 73.58% |
| Average Basic Shares Outstanding | 504.34% | 517.42% | 541.71% | 380.99% | 157.76% |
| Average Diluted Shares Outstanding | 504.34% | 517.42% | 541.71% | 380.99% | 157.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
